Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MRUS 
Merus BV (MRUS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/01/2025: MRUS (2-star) is a SELL. SELL since 4 days. Profits (4.69%). Updated daily EoD!
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
17 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $90.2
1 Year Target Price $90.2
| 13 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 40.26% | Avg. Invested days 37 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.92B USD | Price to earnings Ratio - | 1Y Target Price 90.2 |
Price to earnings Ratio - | 1Y Target Price 90.2 | ||
Volume (30-day avg) 17 | Beta 1.04 | 52 Weeks Range 33.19 - 62.98 | Updated Date 07/1/2025 |
52 Weeks Range 33.19 - 62.98 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.16 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -285.94% |
Management Effectiveness
Return on Assets (TTM) -30.61% | Return on Equity (TTM) -58.66% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3471241510 | Price to Sales(TTM) 71.58 |
Enterprise Value 3471241510 | Price to Sales(TTM) 71.58 | ||
Enterprise Value to Revenue 63.42 | Enterprise Value to EBITDA -4.91 | Shares Outstanding 74476704 | Shares Floating 59561743 |
Shares Outstanding 74476704 | Shares Floating 59561743 | ||
Percent Insiders 2.33 | Percent Institutions 99.34 |
Analyst Ratings
Rating 3 | Target Price 90.2 | Buy 4 | Strong Buy 13 |
Buy 4 | Strong Buy 13 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Merus BV
Company Overview
History and Background
Merus BV is a clinical-stage immuno-oncology company developing innovative full-length multi-specific antibodies, referred to as Biclonicsu00ae. Founded in 2003, the company has focused on developing therapies to treat cancer by harnessing the human immune system. Their Biclonicsu00ae technology platform allows for efficient discovery and development of antibody therapeutics.
Core Business Areas
- Oncology Therapeutics: Focuses on developing multi-specific antibodies for the treatment of various cancers.
- Biclonicsu00ae Platform: Development and optimization of the Biclonicsu00ae technology, a proprietary platform for generating full-length IgG multi-specific antibodies.
- Research and Development: Continues to research and develop new therapeutic candidates and optimize existing ones.
Leadership and Structure
The leadership team consists of a CEO, CFO, CSO, and other key executive positions. The company has a functional organizational structure with departments dedicated to research, development, clinical trials, and business operations.
Top Products and Market Share
Key Offerings
- Zenocutuzumab: Zenocutuzumab is Merus' lead clinical candidate, a Biclonicsu00ae antibody targeting HER2 and HER3 for the treatment of NRG1 fusion-positive cancers. Phase 1/2 eNRGy trial ongoing. Competitors include companies developing targeted therapies against specific cancer mutations, such as Novartis and Roche. Market share is currently not established as the drug is in clinical development.
- Petosemtamab: Petosemtamab is a Biclonicsu00ae antibody targeting EGFR and c-MET for the treatment of solid tumors. Phase 1/2 trial ongoing. Competitors include companies developing EGFR and c-MET inhibitors, such as Janssen Biotech and Eli Lilly. Market share is currently not established as the drug is in clinical development.
Market Dynamics
Industry Overview
The immuno-oncology market is experiencing rapid growth, driven by the development of novel therapies that harness the immune system to fight cancer. The multi-specific antibody segment is becoming increasingly competitive.
Positioning
Merus BV is positioned as a specialized player in the immuno-oncology field, leveraging its proprietary Biclonicsu00ae technology to develop differentiated multi-specific antibody therapeutics. They are focused on targeting specific cancer pathways and mutations.
Total Addressable Market (TAM)
The TAM for cancer therapies is estimated to be in the hundreds of billions of dollars. Merus is positioned to address a portion of this TAM by targeting specific cancer types with high unmet need, focusing on precision medicine.
Upturn SWOT Analysis
Strengths
- Proprietary Biclonicsu00ae technology
- Strong scientific expertise in multi-specific antibody development
- Pipeline of clinical-stage immuno-oncology candidates
- Strategic collaborations with pharmaceutical companies
Weaknesses
- Reliance on clinical trial outcomes
- Limited commercial infrastructure
- High cash burn rate
- Dependence on collaborations
Opportunities
- Positive clinical trial results for lead candidates
- Expansion of pipeline through new Biclonicsu00ae targets
- Partnerships for commercialization
- Acquisition by a larger pharmaceutical company
Threats
- Clinical trial failures
- Competition from other immuno-oncology companies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- JNJ
- LLY
- BMY
Competitive Landscape
Merus competes with large pharmaceutical companies in the immuno-oncology space. Its advantage lies in its proprietary Biclonicsu00ae technology, but it faces challenges in terms of resources and commercial infrastructure.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the advancement of its clinical pipeline and strategic collaborations.
Future Projections: Future growth is dependent on clinical trial outcomes and potential commercialization of its lead candidates.
Recent Initiatives: Recent initiatives include advancing clinical trials for Zenocutuzumab and Petosemtamab and expanding collaborations with pharmaceutical partners.
Summary
Merus BV is a clinical-stage immuno-oncology company with a promising proprietary technology platform. Their clinical pipeline offers potential for significant growth if clinical trials are successful. However, they face challenges related to funding, competition, and regulatory hurdles. Collaborations are crucial for their continued development and potential commercial success. The company's future relies heavily on positive outcomes from its ongoing clinical trials.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Merus BV's official website
- SEC Filings
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Merus BV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2016-05-19 | CEO, President & Executive Director Dr. Sven Ante Lundberg M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 260 | Website https://www.merus.nl |
Full time employees 260 | Website https://www.merus.nl | ||
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.